Page last updated: 2024-11-05

troglitazone and Menopause

troglitazone has been researched along with Menopause in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Malacara, JM1
Fajardo, ME1
Nava, LE1

Trials

1 trial available for troglitazone and Menopause

ArticleYear
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
    Steroids, 2001, Volume: 66, Issue:7

    Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona

2001